Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts

Immunic, Inc. (NASDAQ:IMUX) has received a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $12.67.

Several analysts have commented on the stock. HC Wainwright assumed coverage on shares of Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 target price for the company. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a research note on Tuesday, January 7th.

Insiders Place Their Bets

In related news, Director Richard Alan Rudick purchased 87,300 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares in the company, valued at $100,395. This represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares in the last quarter. Virtu Financial LLC acquired a new stake in Immunic in the 3rd quarter valued at approximately $50,000. Finally, State Street Corp lifted its stake in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Price Performance

IMUX opened at $1.00 on Friday. The firm has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.32. Immunic has a fifty-two week low of $0.97 and a fifty-two week high of $2.11. The company has a market cap of $90.08 million, a price-to-earnings ratio of -0.81 and a beta of 1.88.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.